Published 22 hours ago • loading... • Updated 3 hours agoShow Less IconHRV Pharma invests ₹150 crore to boost peptide, oncology API capacity Summary by Times of IndiaHRV Pharma to invest ₹150 crore to expand synthetic peptide and high-potency oncology API capacity via partner facilities, targeting US/EU markets and complex drugs.Share menu2 Articles2 ArticlesAllLeftCenterRight1Search IconSort IconTimes of IndiaLean RightFactualityOwnershipHRV Pharma invests ₹150 crore to boost peptide, oncology API capacityHRV Pharma to invest ₹150 crore to expand synthetic peptide and high-potency oncology API capacity via partner facilities, targeting US/EU markets and complex drugs.22 hours ago·IndiaRead Full ArticleExpress PharmaFactualityOwnershipHRV Pharma invests Rs 150 crore to expand peptide, high-potent API capabilitiesThe investment strengthens HRV Pharma's presence in high-value pharma segments3 hours agoRead Full ArticleThink freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribeBlindspot Title And LogoStories disproportionately reported by the Left or the RightSee More BlindspotsCoverage DetailsTotal News Sources2Leaning Left0Leaning Right1Center0Last Updated2 hours agoBias Distribution100% RightBias Distribution Too Big Arrow IconToo Big Arrow IconCaret Up Icon100% of the sources lean Right100% RightR 100%Untracked biasFactuality Info IconTo view factuality data please Upgrade to PremiumOwnership Info IconTo view ownership data please Upgrade to VantageTimes of India broke the news in India 22 hours ago on Monday, September 7, 2026.Too Big Arrow IconCaret Down IconSources are mostly out of (0)Similar News TopicsEuropean Union Plus IconIndia Plus IconShow AllBlindspot Title And LogoStories disproportionately reported by the Left or the RightSee More BlindspotsSimilar News TopicsEuropean Union Plus IconIndia Plus IconShow All